Drug Profile
RT 400
Alternative Names: JNJ-39588146; Peptide infusion therapy - Renova Therapeutics; RT-400Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development; Renova Therapeutics
- Class Heart failure therapies; Peptides
- Mechanism of Action Corticotropin-releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Decompensated heart failure
- Discontinued Heart failure
Most Recent Events
- 30 Nov 2022 No development reported - Phase-II for Decompensated heart failure in USA (IV)
- 27 Aug 2019 Phase-II clinical trials in Decompensated heart failure in USA (IV), before August 2019 (Renova Therapeutics pipeline, August 2019)
- 06 Feb 2017 Renova Therapeutics in-licensed stresscopin investigational new drug file from Janssen Pharmaceuticals